Phase 3 Study of Ixazomib in Select Multiple Myeloma Patients Reports Benefits
Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly increases a patient’s progression free survival, according to the results of a Phase 3 clinical trial, published as “Oral Ixazomib, Lenalidomide, and…